ascopubs.org

Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol

With a median follow-up time of 39.6 months, median overall survival was 13.0, 12.7, and 16.3 months for arms 1, 2, and 3, respectively. During induction chemotherapy, grade 3/4 granulocytopenia ...
Healio

‘Worth pursuing’: Radiotherapy with carboplatin-paclitaxel similar to cisplatin for HNSCC

Please provide your email address to receive an email when new articles are posted on . Survival outcomes did not differ for patients with HNSCC who received radiotherapy with carboplatin-paclitaxel ...

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)

Incyte Announces the European Commission Approval of Zynyz (retifanlimab) for First-Line Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) ...
Reuters

Abraxane outperforms Taxol in lung cancer study

CHICAGO (Reuters) - Abraxis Bioscience Inc said its cancer drug Abraxane outperformed the generic drug Taxol in patients with non-small cell lung cancer, without requiring patients to take steroids or ...